Virtual Library
Start Your Search
I. Abou El Khir
Author of
-
+
P1.01 - Poster Session with Presenters Present (ID 453)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Epidemiology/Tobacco Control and Cessation/Prevention
- Presentations: 1
- Moderators:
- Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P1.01-049 - Predictors of High Grade Toxicity of Chemotherapy among Malignant Pleural Mesothelioma Patients (ID 5784)
14:30 - 14:30 | Author(s): I. Abou El Khir
- Abstract
Background:
Malignant pleural mesothelioma is an aggressive thoracic malignancy associated with exposure to asbestos, and its incidence is anticipated to increase during the first half of this century. Chemotherapy is the mainstay of treatment, yet sufficiently robust evidence to substantiate the current standard of care has emerged only in the past 5 years.
Methods:
A retrospective cohort study of 100 MPM patients referred to NCI, Cairo University in 3 years. Detailed data, Pearson's Chi (x2) square and Logistic regression model were used for statistical analysis.
Results:
We found a statistical significant relation between age ( 0.005), male gender (0.002), endemic area residence( 0.001), industrial workers ( 0.018), duration of exposure (0.04), smokers (0.009), Simian virus ( 0.019), P53 ( 0.001), RbP (0.001), PS ( 0.0.16) and development of high grade toxicity of platinum based chemotherapy. Median age = 46 years, only 17% of cases developed high grade toxicity complications of platinum based chemotherapy. Males were 59% of cases. PS, residence, smoking, occupation, history of asbestos exposure, family history, simian virus, P53, Rbp, dyspnea, chest pain, cough, expectoration, haemoptysis, weight loss, fatigue, metastatic symptoms, chronic lung infection, Tuberculous pleuritic, effusion, pleural thickening, Tracheal shift, TNM staging, surgical operations, pathological staging, radiotherapy ,cause of death and chemotherapy toxicity are assessed in our patients.
Conclusion:
Many factors predict high grade chemotherapy toxicity. So, search for target therapy and immunotherapy instead of chemotherapy in this selected group can improve both quality of life and response rate.